144 ·Filed Apr 13, 2026

MLYS

Mineralys Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001964306-26-000202
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

Monitor for actual sale execution; while this is a routine post-vesting sale, the context of recent insider buying ($8.8M) suggests broader confidence, making this isolated sale less concerning. No immediate price impact expected.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
MLYS ▲ +6.00% at T+60d
NEUTRAL call ✓ call won +6.00% · α vs SPY -2.52% · entry $27.32 → $28.96
Entry anchored
Apr 13, 03:59 PM ET
via exchange tick
T+1d
+11.35%
call +11.35% · α +10.57%
$30.42
settled 6mo ago
T+5d
+5.34%
call +5.34% · α +3.95%
$28.78
settled 6mo ago
T+20d
+8.82%
call +8.82% · α +2.53%
$29.73
settled 5mo ago
T+60d
+6.00%
call +6.00% · α -2.52%
$28.96
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Jon Congleton, an officer of Mineralys Therapeutics, filed a Form 144 to notify intent to sell 15,730 shares of common stock, which vested on April 10, 2026, as part of a restricted share unit award. The sale is planned through Merrill Lynch on Nasdaq.

Key Facts

  • Jon Congleton, an officer, intends to sell 15,730 shares of MLYS common stock.
  • Shares were acquired on April 10, 2026, due to vesting of restricted share units granted under the company's equity compensation plan.
  • The filing was submitted on April 13, 2026, with Merrill Lynch listed as the broker.
  • No sales have occurred yet; this is a notice of proposed sale.
  • Recent insider activity shows $8.8M in buys and $579K in sells over the prior 30 days.

Financial Impact

Approximately $422,000 based on recent transaction value (reported $421,979.55).

insider ownershipshare count

Risk Factors

  • Potential perception of negative sentiment if the sale executes near key catalysts or earnings.
  • Limited liquidity risk given the relatively small share volume compared to market cap ($2.2B).

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001964306-26-000202
Document: 0001964306-26-000202-index.html0001964306-26-000202
Document: 0001964306-26-000202.txt0001964306-26-000202
22 reports for MLYS
Performance horizon
67% Hit rate 4 of 6 directional calls best @ T+20▲ +20.97%Jun 11, 2026
Filters
Rows
Reports for MLYS — sortable, filterable
TypeNow
Aug 12, 2026
7w ago
3
NEUTRAL ★ 2/10
$26.09 $28.20▲ +8.09%▲ +9.83%$23.56 (−9.70%)
Jul 23, 2026
10w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.71 $25.65▼ −3.97%▼ −7.59%$23.56 (−11.79%)
Jul 21, 2026
10w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.52 $26.61▼ −3.31%▼ −5.87%$23.56 (−14.39%)
Jul 16, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.08 $26.09▼ −3.66%▼ −7.27%$23.56 (−13.00%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 3/10
$26.89 $26.35▼ −2.01%▲ +0.18%$23.56 (−12.38%)
Jun 29, 2026
13w ago
144
NEUTRAL ★ 3/10
$26.88 $26.71▼ −0.63%▼ −0.35%$23.56 (−12.35%)
Jun 18, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.63 $27.08▲ +9.95%▲ +9.41%$23.56 (−4.34%)
Jun 17, 2026
15w ago
144
NEUTRAL ★ 2/10
$24.63 $27.08▲ +9.95%▲ +9.41%$23.56 (−4.34%)
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 6/10
$23.94 $28.96▲ +20.97%▲ +19.08%$23.56 (−1.59%)
Jun 3, 2026
17w ago
8-K
MIXED ★ 7/10
$25.06 $27.69▲ +10.49%▲ +11.49%$23.56 (−5.99%)
Showing 10 of 22

US Market Status

Market Open — Closes in 3h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access